Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity
- 1 February 1999
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 43 (3) , 565-570
- https://doi.org/10.1016/s0360-3016(98)00451-9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Biochemical disease-free survival following 125I prostate implantationInternational Journal of Radiation Oncology*Biology*Physics, 1997
- 1009 501 Men irradiated for clinically localized prostate cancer (1987 – 1995): Preliminary analysis of the experience at UCSF and affiliated facilitiesInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma.Journal of Clinical Oncology, 1996
- Prostate Specific Antigen Based Disease Control Following Ultrasound Guided sup 125 Iodine Implantation for Stage T1/T2 Prostatic CarcinomaJournal of Urology, 1995
- Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcomeUrology, 1995
- SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMYUrologic Clinics of North America, 1993
- Prostate-Specific Antigen Testing in Untreated and Treated Prostatic AdenocarcinomaMayo Clinic Proceedings, 1990
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. I. Untreated PatientsJournal of Urology, 1989
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987